Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.51 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199233 | 0.86 | LMNA (0.73) | PARP14LMNAHPGDTSHRMEN1 | |
| SCHEMBL1200203 | 0.85 | LMNA (0.62) | PARP14LMNAHPGDTSHRKCNH2 | |
| SCHEMBL1198764 | 0.85 | KCNH2 (0.67) | PARP14LMNAHPGDTSHRMEN1 | |
| SCHEMBL2747338 | 0.82 | LMNA (0.64) | PARP14LMNAHPGDTSHRMEN1 | |
| SCHEMBL7537253 | 0.82 | IDH2 (0.54) | LMNATSHRMEN1KMT2AGAA | |
| SCHEMBL532885 | 0.81 | LMNA (0.78) | LMNAHPGDTSHRMEN1KMT2A | |
| SCHEMBL4572271 | 0.81 | TSHR (0.62) | LMNAHPGDTSHRKMT2AKCNH2 | |
| SCHEMBL2749317 | 0.81 | LMNA (0.62) | LMNAHPGDTSHRMEN1KMT2A | |
| SCHEMBL7569668 | 0.80 | KMT2A (0.76) | LMNATSHRMEN1KMT2AGAA | |
| SCHEMBL2748573 | 0.80 | PARP14 (0.71) | PARP14LMNAHPGDTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| EP-2207772-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009044311-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR | ENCYSIVE PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044311-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR | ENCYSIVE PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | CCR9, CCR1, CCR10 | PARP14 2769/4885LMNA 4182/4885HPGD 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.